Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect

被引:18
作者
Byrne, JL
Carter, GI
Ellis, I
Haynes, AP
Russell, NH
机构
[1] CITY HOSP,DEPT HISTOPATHOL,NOTTINGHAM NG5 1PB,ENGLAND
[2] UNIV NOTTINGHAM,NOTTINGHAM NG7 2RD,ENGLAND
关键词
autologous graft-versus-host disease (GVHD); multiple myeloma; graft-versus-myeloma (GVM) effect; PBSC transplantation;
D O I
10.1038/sj.bmt.1700922
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The development of GVHD following allogeneic BMT is known to be closely associated with significant antileukaemic activity, Immunological graft-versus-leukaemia (GVL) effects are now well established and are commonly exploited in the treatment of leukaemic relapse following allogeneic transplantation by the use of donor lymphocyte infusions, More recently a graft-versus-myeloma (GVM) effect following allogeneic transplantation has been documented, suggesting that eradication of haematological malignancies following allogeneic transplantation is achieved at least in part by immunological mechanisms, It is now also established that spontaneous GVHD can occur following autologous transplantation and can be induced by cyclosporin A administration, However, there is only limited evidence that the development of autologous GVHD has an antitumour effect, We report for the first time the development of autologous GVHD following PBSC transplantation for myeloma apparently resulting in a GVM effect.
引用
收藏
页码:517 / 520
页数:4
相关论文
共 13 条
[1]  
BROWN R, 1996, BLOOD S1, V88
[2]   CYCLOSPORINE-INDUCED GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HEMATOLOGICAL MALIGNANCIES [J].
CARELLA, AM ;
GAOZZA, E ;
CONGIU, A ;
CARLIER, P ;
NATI, S ;
TRUINI, M ;
CASTELLANETA, A ;
VIALE, M .
ANNALS OF HEMATOLOGY, 1991, 62 (05) :156-159
[3]  
GELLER RB, 1989, BLOOD, V74, P1165
[4]   Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue [J].
Giralt, S ;
Weber, D ;
Colome, M ;
Dimopoulos, M ;
Mehra, R ;
VanBesien, K ;
Gajewski, J ;
Andersson, B ;
Khouri, I ;
Przepiorka, D ;
vonWolff, B ;
Delasalle, K ;
Korbling, M ;
Seong, D ;
Alexanian, R ;
Champlin, R .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :667-673
[5]   The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon [J].
Gryn, J ;
Johnson, E ;
Goldman, N ;
Devereux, L ;
Grana, G ;
Hageboutros, A ;
Fernandez, E ;
Constantinou, C ;
Harrer, W ;
Viner, E ;
Goldberg, J .
BONE MARROW TRANSPLANTATION, 1997, 19 (03) :221-226
[6]   ACUTE GRAFT-VS-HOST DISEASE - DEVELOPMENT FOLLOWING AUTOLOGOUS AND SYNGENEIC BONE-MARROW TRANSPLANTATION [J].
HOOD, AF ;
VOGELSANG, GB ;
BLACK, LP ;
FARMER, ER ;
SANTOS, GW .
ARCHIVES OF DERMATOLOGY, 1987, 123 (06) :745-750
[7]  
JONES RJ, 1989, LANCET, V1, P754
[8]  
KENNEDY MJ, 1991, AM SOC CLIN ONCOL, V10, P43
[9]   DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].
KOLB, HJ ;
MITTERMULLER, J ;
CLEMM, C ;
HOLLER, E ;
LEDDEROSE, G ;
BREHM, G ;
HEIM, M ;
WILMANNS, W .
BLOOD, 1990, 76 (12) :2462-2465
[10]   Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit [J].
McQuaker, IG ;
Hunter, AE ;
Pacey, S ;
Haynes, AP ;
Iqbal, A ;
Russell, NH .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :451-457